Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.48 |
| ▸ | NPY5R | Q15761 | 11/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | KCNJ6 | P48051 | 1/20 | 0.44 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.44 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2199917 | 0.87 | POLB (0.51) | POLBKMT2ANOTUMNPY5RLMNA | |
| SCHEMBL2204423 | 0.84 | NPY5R (0.47) | POLBKMT2ANOTUMNPY5R | |
| SCHEMBL2202029 | 0.83 | POLB (0.59) | POLBKMT2ANOTUMNPY5R | |
| SCHEMBL2200696 | 0.82 | POLB (0.58) | POLBKMT2ANOTUMNPY5R | |
| SCHEMBL2199944 | 0.82 | POLB (0.53) | POLBKMT2ANOTUMNPY5RLMNA | |
| SCHEMBL2199954 | 0.81 | KMT2A (0.44) | POLBKMT2ALMNA | |
| SCHEMBL2200100 | 0.79 | KMT2A (0.48) | POLBKMT2ANPY5RLMNA | |
| SCHEMBL2199984 | 0.76 | POLB (0.52) | POLBKMT2ANOTUMNPY5R | |
| SCHEMBL2201779 | 0.76 | KMT2A (0.58) | POLBKMT2ANOTUMNPY5RLMNA | |
| SCHEMBL2201707 | 0.76 | KMT2A (0.54) | POLBKMT2ANOTUMNPY5RLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977358-B2 | Pyrazol derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-07-12 | — | — | US | disclosed |
| EP-2182953-A2 | NEW PYRAZOL DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2010-05-12 | — | — | EP | disclosed |
| US-20090029963-A1 | PYRAZOL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-29 | — | — | US | disclosed |
| WO-2009013211-A2 | NEW PYRAZOL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029963-A1 | PYRAZOL DERIVATIVES | CCR1, CCR3, CCRL2 | POLB 4350/4885KMT2A 4057/4885NOTUM 4406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.